title: Silicon drain with channels along the sides for internal biliary stenting of hepaticojejunostomy in hepatic hilar malignancies.
abstract: BACKGROUND
  We compared two types of stents in patients who underwent surgery for hepatic hilar malignancies.
  
  
  METHODS
  Twenty-one patients with hepatic hilar malignancies who underwent hepatectomy were randomly assigned to one of two groups. A 5-Fr silicon drain with an internal lumen and side holes was used for the hepaticojejunostomy in one group (intraluminal stent group), and a 10-Fr silicon drain with channels along the sides was used in the other (channel stent group).
  
  
  RESULTS
  Leakage developed in four patients (36.4%) in the intraluminal stent group versus two (20.0%) in the channel stent group. Cholangitis developed in three patients with leakage (27.3%) in the intraluminal stent group versus no patient in the channel stent group. After operation, the times required for the serum alkaline phosphatase and total bilirubin levels to return to the normal range were significantly shorter in the channel stent group (5.3 +/- 2.9, 3.8 +/- 2.2 days) than in the intraluminal stent group (17.0 +/- 5.8, 9.4 +/- 5.7 days) (P < 0.0001, P = 0.0093).
  
  
  CONCLUSIONS
  A 10-Fr silicon drain with channels is superior to a 5-Fr silicon drain with an internal lumen for internal biliary stenting of hepaticojejunostomy in patients with hepatic hilar malignancies.
authors: Department of Surgery, Nippon Medical School, Tokyo, Japan. hiroshiy@nms.ac.jp
authors: Hiroshi
authors: H
authors: Yoshida
authors: Yasuhiro
authors: Y
authors: Mamada
authors: Nobuhiko
authors: N
authors: Taniai
authors: Yoshiaki
authors: Y
authors: Mizuguchi
authors: Daisuke
authors: D
authors: Kakinuma
authors: Yoshinori
authors: Y
authors: Ishikawa
authors: Tomohiro
authors: T
authors: Kanda
authors: Koichi
authors: K
authors: Bando
authors: Koho
authors: K
authors: Akimaru
authors: Takashi
authors: T
authors: Tajiri
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D017734:Bile Ducts, Extrahepatic / Q000601:surgery*; D001661:Biliary Tract Neoplasms / Q000601:surgery*; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002761:Cholangitis / Q000097:blood / Q000209:etiology; D004322:Drainage / Q000009:adverse effects / Q000295:instrumentation*; D005260:Female; D005706:Gallbladder Neoplasms / Q000601:surgery*; D006498:Hepatectomy; D006801:Humans; D007582:Jejunostomy / Q000009:adverse effects / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011474:Prosthesis Design; D018570:Risk Assessment; D012825:Silicon; D015607:Stents; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000469:Alkaline Phosphatase; D001663:Bilirubin; D012825:Silicon